血浆中可溶性HLA-E分子水平与其基因多态性及白血病的相关性研究  

Study on the Relationship between the Level of Soluble HLA-E Molecules in Plasma and Gene Polymorphism and Leukemia

作　　者：孙丽艳 徐筠娉[1] SUN Li-Yan;XU Yun-Ping(Institute of Transfusion Medicinehenzhen Blood Center,Shenzhen 518035,Guangdong Province,China)

机构地区：[1]深圳市血液中心,输血医学研究所,广东深圳518035

出　　处：《中国实验血液学杂志》2022年第2期346-350,共5页Journal of Experimental Hematology

基　　金：广东省自然科学基金(2020A1515010387);深圳市科技创新委基础研究项目(JCYJ20180302153439758);深圳市医疗卫生三名工程项目(SZSM201811092);深圳卫生计生系统科研项目(SZGW2017005);深圳市医学重点学科(SZXK070)。

摘　　要：目的:探索中国深圳地区人群血浆中可溶性HLA-E(s HLA-E)分子水平与其基因多态性及白血病的相关性。方法:利用酶联免疫吸附方法检测103例白血病患者及113名健康献血者血浆s HLA-E分子水平,采用PCR-SBT方法确定其中73例白血病患者及76名健康献血者的HLA-E基因分型情况。结果:103例白血病患者血浆s HLA-E分子水平明显高于113名健康献血者(P<0.001);与113名健康献血者相比,77例髓系白血病患者血浆s HLA-E分子水平明显升高(P<0.001)。在白血病及髓系白血病中血浆s HLA-E浓度为0-199 ng/ml的患者所占人数百分比分别为37.86%、32.47%,明显低于健康献血者的53.98%,比较差异具有统计学意义(P<0.05,P<0.01);而血浆s HLA-E浓度>400 ng/ml的患者所占人数百分比分别为33.01%、36.36%,明显高于健康献血者的13.28%,比较差异亦有统计学意义(P=0.001,P<0.001)。无论是健康献血者还是白血病患者,不同的HLA-E基因型组间s HLA-E分子水平无显著统计学差异(P>0.05)。结论:白血病(尤其是髓系白血病)患者血浆s HLA-E分子水平明显高于健康献血者,但不同的HLA-E基因型并未影响s HLA-E分子水平,可以设定s HLA-E分子浓度的界值(建议风险值>400 ng/ml),从而评估某些白血病前状态患者的患病风险。Objective: To explore the relationship between the level of soluble HLA-E(s HLA-E) molecules in plasma and gene polymorphism and leukemia in Shenzhen of China. Methods: Enzyme-linked immunosorbent assay was used to detect s HLA-E level in plasma of 103 leukemia patients and 113 healthy blood donors. PCR-SBT was used to identify the HLA-E genotype of 73 leukemia patients and 76 healthy blood donors. Results: The level of plasma s HLA-E of 103 leukemia patients was significantly higher than that of 113 healthy blood donors(P<0.001);And the level of plasma s HLA-E in 77 myeloid leukemia patients was also significantly higher(P<0.001). The percentage of patients with plasma s HLA-E concentration of 0-199 ng/ml in leukemia and myeloid leukemia patients was 37.86% and 32.47%, respectively, which was significantly lower than 53.98% of healthy donors, the difference was statistically significant(P<0.05, P<0.01);While, when the plasma s HLA-E concentration was more than 400 ng/ml, the percentage was 33.01% and 36.36%, respectively, which was significantly higher than 13.28% of healthy donors, the difference was also statistically significant(P=0.001, P<0.001). There was no significant difference in the level of plasma s HLA-E among different HLA-E genotypes(P>0.05), whether healthy blood donors or leukemia patients. Conclusion: The level of plasma s HLA-E in patients with leukemia(especially myeloid leukemia) is significantly higher than that of healthy blood donors, but different HLA-E genotypes do not affect the level of plasma s HLA-E. A cut-off value for the concentration of plasma s HLA-E(recommended risk value >400 ng/ml) can be set to assess the risk of certain preleukemia patients.

关 键 词：可溶性HLA-E分子 基因型 白血病 髓系白血病 淋系白血病 

分 类 号：R733[医药卫生—肿瘤]